45 results
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
25 Apr 24
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
8:03am
31, 2023. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
16 Apr 24
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
7:34am
the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Mar 24
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4:32pm
are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
2(b) on the Trading Market at the time of sale of such Shares.
(ii)The Company acknowledges and agrees that (A) there can be no assurance … of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
have purchased them.
There can be no assurance that we will not be a passive foreign investment company, or PFIC, for United States federal income … , there can be no assurance with respect to our status as a PFIC for our current taxable year or any subsequent taxable year. We urge U.S. Holders to consult
6-K
EX-99.1
46bwt4tk
21 Dec 23
Current report (foreign)
7:34am
424B3
238jtn99 db95
20 Dec 23
Prospectus supplement
4:03pm
6-K
EX-99.1
a9ide3ys
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
6-K
EX-99.1
btltobq5cz6v06l
14 Dec 23
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
7:43am
F-3
EX-23.1
wgu08vvkg9hmv8 wdge
5 Dec 23
Shelf registration (foreign)
4:06pm
F-3
qb3r9zu qx48y9sq
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
4qz3 iyouo
12 Sep 23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
7:49am
6-K
EX-99.1
5eytwa14np
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-99.1
l5y 7d56sl1igv
3 Aug 23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
8:39am
6-K
EX-99.1
fyzaakpx9a
18 Jul 23
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
7:58am
6-K
EX-99.1
xh293k
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am
6-K
EX-99.1
usxfdaqqn2dhzqmk
4 May 23
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
7:56am